SAN DIEGO — Patients with idiopathic pulmonary fibrosis (IPF) had significant improvements in lung function and reversal of lung fibrosis measures after 12 weeks of therapy with an investigational ...
Promising results from a phase 2 trial of ENV-101, a novel hedgehog inhibitor, showed improvement in lung function and reduction of fibrosis in patients with idiopathic pulmonary fibrosis, said Paul ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback